Kicking off the Microdose Wonderland conference in Miami, Cybin Inc announced it will be moving its psilocybin analogue – CYB003 – into clinical trials.
The findings from a Phase II A/B study, which is the world’s first study on ketamine-assisted psychotherapy for alcohol use disorder, will be published in the...
A free, virtual event is to explore the use of psychedelics for alcohol use disorder and binge drinking.